MX336332B - Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia. - Google Patents

Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia.

Info

Publication number
MX336332B
MX336332B MX2012002327A MX2012002327A MX336332B MX 336332 B MX336332 B MX 336332B MX 2012002327 A MX2012002327 A MX 2012002327A MX 2012002327 A MX2012002327 A MX 2012002327A MX 336332 B MX336332 B MX 336332B
Authority
MX
Mexico
Prior art keywords
kinase inhibitors
therapy
prodrug forms
kinase
prodrug
Prior art date
Application number
MX2012002327A
Other languages
English (en)
Other versions
MX2012002327A (es
Inventor
William Alexander Denny
William Robert Wilson
Adam Vorn Patterson
Jeffrey Bruce Smaill
Guo-Liang Lu
Robert Forbes Anderson
Ho Huat Lee
Amir Ashoorzadeh
Huai-Ling Annie Hsu
Andrej Maroz
Stephen Michael Frazer Jamieson
Alexandra Marie Mowday
Kendall Marie Carlin
Original Assignee
Auckland Uniservices Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auckland Uniservices Ltd filed Critical Auckland Uniservices Ltd
Publication of MX2012002327A publication Critical patent/MX2012002327A/es
Publication of MX336332B publication Critical patent/MX336332B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de pirido [3,4-dl pirimidina de la fórmula (I) (ver fórmula(I)) adecuados como inhibidores de cinasa, a inhibidores de cinasa en forma de profármaco, a su uso en composiciones y a medicamentos que son adecuados para el tratamiento de enfermedades relacionadas con actividad de cinasa tales como cánceres.
MX2012002327A 2009-09-02 2010-09-02 Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia. MX336332B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ57945809 2009-09-02
PCT/NZ2010/000174 WO2011028135A1 (en) 2009-09-02 2010-09-02 Kinase inhibitors, prodrug forms thereof and their use in therapy

Publications (2)

Publication Number Publication Date
MX2012002327A MX2012002327A (es) 2012-04-10
MX336332B true MX336332B (es) 2016-01-15

Family

ID=43649498

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002327A MX336332B (es) 2009-09-02 2010-09-02 Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia.

Country Status (14)

Country Link
US (2) US9101632B2 (es)
EP (1) EP2473509A4 (es)
JP (2) JP5925680B2 (es)
KR (1) KR20120076350A (es)
CN (2) CN102574846B (es)
AU (1) AU2010290199B2 (es)
BR (1) BR112012004720B1 (es)
CA (1) CA2771016A1 (es)
IL (1) IL218182B (es)
MX (1) MX336332B (es)
NZ (1) NZ598144A (es)
RU (1) RU2568639C2 (es)
WO (1) WO2011028135A1 (es)
ZA (1) ZA201200994B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2568639C2 (ru) * 2009-09-02 2015-11-20 Окленд Юнисервисиз Лимитед Ингибиторы киназы, их пролекарственные формы и их применение в терапии
EP3226869A4 (en) * 2014-12-03 2018-07-18 Auckland UniServices, Ltd. Kinase inhibitor prodrug for the treatment of cancer
AU2016344040B2 (en) 2015-11-01 2020-12-10 The Regents Of The University Of Colorado, A Body Corporate Wee 1 kinase inhibitors and methods of making and using the same
AU2018229148B2 (en) * 2017-03-03 2022-08-04 Auckland Uniservices Limited FGFR kinase inhibitors and pharmaceutical uses
SG11202002060XA (en) * 2017-09-08 2020-04-29 Univ Colorado Regents Compounds, compositions and methods for treating or preventing her-driven drug-resistant cancers
WO2019125184A1 (en) 2017-12-19 2019-06-27 Auckland Uniservices Limited Use of biomarker in cancer therapy
AU2019227823B2 (en) * 2018-02-28 2024-12-12 The Regents Of The University Of Colorado, A Body Corporate WEE1 kinase inhibitors and methods of treating cancer using the same
US20220194940A1 (en) * 2019-04-25 2022-06-23 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of tyrosine kinase
WO2021127456A1 (en) 2019-12-19 2021-06-24 Rain Therapeutics Inc. Methods of inhibiting epidermal growth factor receptor proteins
WO2025020886A1 (zh) * 2023-07-27 2025-01-30 浙江星浩澎博医药有限公司 氮杂喹唑啉环衍生物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE236881T1 (de) 1995-08-18 2003-04-15 Auckland Uniservices Ltd Durch strahlung aktivierte cytotoxin therapie
SI0795334T1 (sl) * 1996-03-12 2006-06-30 Sanofi Aventis Deutschland Predzdravila za zdravljenje tumorjev in vnetnih bolezni
HU228446B1 (en) * 1996-04-12 2013-03-28 Warner Lambert Co Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) * 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
DE602004004259T2 (de) * 2003-04-16 2007-11-15 F. Hoffmann-La Roche Ag (6-(PHENOXY)-PYRIDOi3,4-DöPYRIMIDIN-2-YL)-AMIN DERIVATE ALS P38 KINASE INHIBITOREN ZUR BEHANDLUNG VON ENTZÜNDLICHEN ERKRANKUNGEN WIE RHEUMATOIDER ARTHRITIS
SI1948180T1 (sl) * 2005-11-11 2013-06-28 Boehringer Ingelheim International Gmbh Kombinacijsko zdravljenje raka, ki obsega EGFR/HER2 inhibitorje
CN101003514A (zh) 2006-01-20 2007-07-25 上海艾力斯医药科技有限公司 喹唑啉衍生物、其制备方法及用途
WO2008151253A1 (en) 2007-06-04 2008-12-11 Threshold Pharmaceuticals, Inc. Hypoxia activated prodrugs of antineoplastic agents
AU2010221818A1 (en) * 2009-03-11 2011-10-06 Auckland Uniservices Limited Prodrug forms of kinase inhibitors and their use in therapy
RU2568639C2 (ru) * 2009-09-02 2015-11-20 Окленд Юнисервисиз Лимитед Ингибиторы киназы, их пролекарственные формы и их применение в терапии

Also Published As

Publication number Publication date
JP2016094432A (ja) 2016-05-26
CN102574846B (zh) 2014-12-03
RU2012112396A (ru) 2013-10-10
US9101632B2 (en) 2015-08-11
KR20120076350A (ko) 2012-07-09
WO2011028135A1 (en) 2011-03-10
EP2473509A1 (en) 2012-07-11
IL218182B (en) 2018-03-29
US20120202832A1 (en) 2012-08-09
US20160031877A1 (en) 2016-02-04
RU2568639C2 (ru) 2015-11-20
CN102574846A (zh) 2012-07-11
NZ598144A (en) 2014-01-31
BR112012004720A2 (pt) 2016-03-15
JP2013503859A (ja) 2013-02-04
AU2010290199B2 (en) 2016-10-27
AU2010290199A1 (en) 2012-03-01
MX2012002327A (es) 2012-04-10
CN104496982A (zh) 2015-04-08
EP2473509A4 (en) 2013-04-17
JP5925680B2 (ja) 2016-05-25
CA2771016A1 (en) 2011-03-10
BR112012004720B1 (pt) 2021-06-29
IL218182A0 (en) 2012-07-31
ZA201200994B (en) 2012-10-31

Similar Documents

Publication Publication Date Title
MX336332B (es) Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia.
MY156727A (en) N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
TN2012000062A1 (en) Jak 2 inhibitors and their use for the treatment of myeloproliferative deseases and cancer
MX2011012337A (es) Nuevos derivados de pirimidina y su uso en el tratamiento de cancer y de otras enfermedades.
TN2015000368A1 (en) Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
PH12012501164A1 (en) Imidazopyridine derivatives as jak inhibitors
MX2009008953A (es) Compuestos como inhibidores de angiogenesis.
MX2009009843A (es) Compuestos espiro sustituidos como inhibidores de la angiogenesis.
MX2010003668A (es) Derivados de purina sustituidas con primidina.
BR112013012502A2 (pt) pirrolopiridina ciclobutil substituída e derivados de pirrolopirimidina derivativos como inibidores de jak
MX2013008296A (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
MX2010006748A (es) Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2.
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
WO2012016186A8 (en) Macrocyclic kinase inhibitors and uses thereof
MY189427A (en) Pyrazolyl quinoxaline kinase inhibitors
TN2012000249A1 (en) Pyrazine derivatives and their use in the treatment of neurological disorders
AU2009282962A8 (en) Compounds as kinase inhibitors
PH12013500648A1 (en) Quinazolin-4 (3h) -one derivatives used as pi3 kinase inhibitors
MX2012013274A (es) Novedosos derivados de la pirimidina.
MX2012000166A (es) Compuestos de quinazolina que contienen fosforo y metodos de uso de los mismos.
MX349550B (es) 1,7-diazacarbazoles y metodos de uso.
MX2013002384A (es) Compuestos quinazolina y metodos para utilizarlos.
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
MX2012005225A (es) Compuestos y composiciones de purina n-7 sustituida y pirazolopirimidina, y metodos de uso.